In short
Clinical trials are studying Ly3541860 in adults with relapsing multiple sclerosis. These trials are designed to evaluate how well it works and to measure safety-related outcomes through MRI brain scans and other study checks. The available trial data focus on people with relapsing MS.
Key points
- Clinical trial data for Ly3541860 focus on adults with relapsing multiple sclerosis. The listed study is a Phase 2 interventional trial with 83 participants. Researchers are mainly measuring the cumulative number of new T1 gadolinium-enhancing brain lesions on MRI. The study compares Ly3541860 with placebo to evaluate efficacy. The trial has been completed.
Trial overview
The available trial data describe one Phase 2 interventional study of Ly3541860 in adults with relapsing multiple sclerosis. The study was completed and enrolled 83 participants.
Who participated
This study focused on adult participants with relapsing multiple sclerosis (RMS). The trial data do not provide more detailed eligibility rules, such as age limits beyond adulthood or other medical requirements.
What was measured
The main outcome was the cumulative number of new T1 gadolinium-enhancing lesions seen on MRI scans of the brain. In simple terms, the study used brain imaging to count new areas that may show active disease.
Study design and comparison
The brief summary says the study aimed to evaluate the efficacy of Ly3541860 versus placebo on the number of new T1 GdE MRI brain lesions in participants with RMS. A placebo is a look-alike treatment used for comparison and does not contain the active study drug.
The listed interventions included 0.9% sodium chloride, gadoteric acid, and Ly3541860 as a solution for injection. The trial data do not explain the full treatment schedule or how these interventions were assigned.
What the trial data show
From the provided data, the key point is that researchers studied Ly3541860 in a completed Phase 2 trial for relapsing multiple sclerosis. The main focus was on MRI brain lesions, which are used to track disease activity in MS. No outcome results are included in the source data, so the trial record here tells us about the study plan and target group, not the final findings.